At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the results of the randomised, double-blind, phase 2 TERRAIN trial, which compared enzalutamide, a novel androgen receptor signalling inhibitor, with bicalutamide, a non-steroidal antiandrogen, for men with metastatic castrate-resistant prostate cancer.
>